Imatinib Mesylate in Treating Patients With Myelofibrosis
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and how well
it works in treating patients with myelofibrosis.